FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced Pancreatic Carcinoma By Ogkologos - May 26, 2025 413 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PRODIGE 29-UCGI 26 (NEOPAN) study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR Oral Cancer Taught Me How Much Words Matter April 21, 2021 FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumours... October 29, 2020 Breaking: Longtime Broadcast Journalist Cokie Roberts Dies At 75 September 17, 2019 FDA Approves Pembrolizumab for Advanced MSI-H/dMMR Endometrial Carcinoma April 5, 2022 Load more HOT NEWS Nivolumab-Based Combinations Improve Survival in Advanced Esophageal Cancer No Improvement in OS with Adding Palbociclib to Letrozole for the... RANO and Modified RANO Criteria Demonstrate Similar Correlations Between PFS and... ESMO Immuno-Oncology Virtual Congress 2020
